Table 1 Baseline characteristics of the participants
Pioglitazone Group (n = 36) | Empagliflozin Group (n = 37) | P value** | |
|---|---|---|---|
Age (yrs.) | 52 ± 7 | 52 ± 7 | 0.74 |
Female (%) | 58.3% | 54.0% | 0.71 |
BMI (kg/m2) | 31.3 ± 5.0 | 31.0 ± 3.8 | 0.80 |
Diabetes duration (yrs.) | 7.9 ± 5.3 (1.5–24) | 8.0 ± 6.1 (0.5–30) | 0.88 |
FBS (mg/dl) | 165 ± 49 | 177.57 ± 66.40 | 0.37 |
HbA1c (%) | 8.4 ± 1.1 | 8.6 ± 1.1 | 0.47 |
TG (mg/dl) | 212.8 ± 127.9 | 161.7 ± 70.6 | 0.04 |
Tchol (mg/dl) | 158.3 ± 32.4 | 146.0 ± 30.3 | 0.10 |
LDL-C (mg/dl) | 100.1 ± 20.6 | 96.3 ± 26.0 | 0.49 |
HDL-C (mg/dl) | 46.7 ± 9.3 | 44.8 ± 8.9 | 0.37 |
ALT (IU/L) | 31.5 ± 12.2 | 31.8 ± 17.6 | 0.93 |
AST (IU/L) | 23.0 ± 7.7 | 25.1 ± 14.5 | 0.43 |
TyG* | 9.6 ± 0.6 | 9.4 ± 0.7 | 0.26 |
CAP (dB/m) | 329.8 ± 19.1 | 325.1 ± 18.4 | 0.29 |
LSM (kPa) | 7.2 ± 2.5 | 7.4 ± 3.4 | 0.75 |